Companies covered: Celyad SA (ADR) (NASDAQ:CYAD), bluebird bio, Inc. (NASDAQ:BLUE), Spark Therapeutics, Inc. (NASDAQ:ONCE), Gilead Sciences, Inc. (NASDAQ:GILD), Novartis AG (NYSE:NVS), Rocket Pharmaceuticals (NASDAQ:RCKT), Biogen Inc. (NASDAQ:BIIB), Ionis Pharmaceuticals Inc (NASDAQ:IONS), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Sangamo Therapeutics, Inc. (NASDAQ:SGMO), Pfizer, Inc. (NYSE:PFE), Abeona Therapeutics (NASDAQ:ABEO), LogicBio Therapeutics (NASDAQ:LOGC), Krystal Biotech (NASDAQ:KRYS), Global Blood Therapeutics (NASDAQ:GBT), Lonza Group AG (ADR) (OTCMKTS:LZAGY), Roche Holdings Ltd. (ADR) (OTCMKTS:RHHBY), Celgene Corporation (NASDAQ:CELG), Bristol-Myers Squibb Company (NYSE:BMY), uniQure N.V. (NASDAQ:QURE), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), CRISPR Therapeutics AG (NASDAQ:CRSP), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Voyager Therapeutics (NASDAQ:VYGR), Lysogene SA (EPA:LYS), Nightstar Therapeutics PLC (NASDAQ:NITE), Denali Therapeutics (NASDAQ:DNLI), Arcturus Therapeutics Ltd. (NASDAQ:ARCT), NeuBase Therapeutics, Inc. (NASDAQ:NBSE), Bio-Path Holdings, Inc. (NASDAQ:BPTH), Regenxbio Inc (NASDAQ:RGNX), PTC Therapeutics, Inc. (NASDAQ:PTCT), Amicus Therapeutics, Inc. (NASDAQ:FOLD), Axovant Sciences Ltd. (NASDAQ:AXGT), Ophthotech Corporation (NASDAQ:OPHT), MeiraGTx Holdings PLC (NASDAQ:MGTX), Editas Medicine (NASDAQ:EDIT), Intellia Therapeutics (NASDAQ:NTLA), Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Illumina, Inc. (NASDAQ:ILMN), Amazon.com, Inc. (NASDAQ:AMZN), Cellectis S.A. (NASDAQ:CLLS), AquaBounty Technologies, Inc. (NASDAQ:AQB), Biocon Ltd. (BOM:532523), Invitae Corp. (NYSE:NVTA)
